TheranosticTrials.org

Clinical Trial · NCT01620749

Of 18F MEL050 Using PET/CT in Metastatic Melanoma

Overview

The purpose of this study is to investigate the safety and potential effectiveness of the imaging compound 18F MEL050 for finding sites of melanoma.

Sponsor

Unknown Organization

Phase

Early Phase 1

Contacts

Grant McArthur (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT01620749

Drug / Compound

MEL050

Isotope(s):
Target(s):
  • MC1R
Ligand Class: Small Molecules

Eligibility

Inclusion

  • Male and female patients with histologically confirmed melanoma
  • At least one site of metastatic disease, as demonstrated on the pre-study 18F FDG PET/CT scan performed as part of routine clinical care

Exclusion

  • Patients with urinary incontinence or patients who cannot comfortably hold their urine for more than 90 minutes
  • Patients whose only metastatic lesion is in the Central Nervous System
  • Systemic anti-melanoma therapy within the 2 weeks prior to the pre-study 18F FDG PET/CT scan until after the 18F MEL050 PET/CT scan